FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry, particularly to a recovered monoclonal anti-LOXL2 antibody or its antigen-binding fragment, as well as conjugates containing them. What is disclosed is a pharmaceutical composition for treating a disease related to angiogenesis, fibrosis, tumour or metastases, containing the above recovered monoclonal anti-LOXL2 antibody or its antigen-binding fragment in an effective amount. The invention also refers to a method for determining and/or measuring LOXL2 in a biological sample, to a method for inhibiting LOXL2 activity, to a method for reducing growth of LOXL2-expressing tumour in an individual in need thereof, to a method for inhibiting angiogenesis in the individual in need thereof, to a method for suppressing a fibrous disease in the individual in need thereof, as well as to a method for monitoring an individual's response to an anti-LOXL2 therapy with using the above antibody or its antigen-binding fragment and the above conjugate.
EFFECT: invention enables treating the LOXL2-related diseases effectively.
28 cl, 6 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF PULMONARY HYPERTENSION TREATMENT | 2017 |
|
RU2748278C2 |
| CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROUS DISEASES | 2010 |
|
RU2561672C2 |
| ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY | 2013 |
|
RU2656153C1 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
